The bill is aimed at slowing the “revolving door” between federal agencies and pharmaceutical companies.
“The pharmaceutical industry has a deep-rooted and strong influence in Washington, and a revolving door between drug companies and government cannot undermine the safety of our communities,” Sen. Tammy Baldwin, D-Wis., who sponsored the bill, told The Washington Post.
In addition to the two-year period barring FDA and DEA officials from assisting drugmakers, the bill also expands the definition of “lobbying contact” to include taking part in strategy sessions and limits the issues pharmaceutical industry executives could help with if they take a role in a government agency.
Due to the complexity of drug laws, it is not uncommon for pharma executives take on government roles or for federal employees to switch to the private sector, according to the report.
Currently there are regulations in place to prevent conflicts of interest in the “revolving door” phenomenon, such as a lifetime ban on participating personally on a matter that the official handled while at the government. However, experts say these laws are easily avoidable.
More articles on leadership and management:
Study: Gender inequality is due to bias, not behavior
Senate considers Medicare, HHS extenders: 7 things to know
HHS seeks to reduce burden on religious groups to participate in healthcare
At Becker's 4th Annual CEO + CFO Roundtable, taking place November 2–5 in Chicago, more than 1,500 hospital and health system executives tackle decisions that determine whether organizations thrive or merely survive: protecting margins under cost pressure, choosing where to grow, renegotiating payer relationships, stabilizing the workforce and proving real ROI on technology. This is where leaders work through them together, face-to-face. Apply for complimentary registration now.